23 May 2023
Latham & Watkins Advises Coherus in Pricing of Public Offering of Common Stock
Advising firms
Deal team
11 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ben Potter Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Phillip Stoup Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Steven Schmulenson | Latham & Watkins LLP | Associate | corporate | Los Angeles |
| Theresa Bloom | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Chelsi DeTurk | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Rebecca Dixon | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Elizabeth Richards | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | regulatory | Bay Area |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| James Metz | Latham & Watkins LLP | Partner | benefits | Bay Area |
| Jekkie Kim | Latham & Watkins LLP | Partner | IP | Bay Area |
Stated terms
- Stated value
- USD 4.25 (US$4.25 per share)
- What the figure measures
- Per share
- Client
- Coherus BioSciences, Inc.Issuer
- Counterparties
- Not stated